Clinical study on the effect of remazolam besylate on the incidence of hypoxemia in obese patients during painless gastrointestinal endoscopy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052707

Enrollment

Unknown

Registered

2021-11-03

Start date

2022-01-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal disease

Interventions

Remazolam besylate group:Remazolam besylate

Propofol group:Propofol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. Body mass index (BMI) >= 30 kg/m^2; 3. Patients who are willing to accept sedation/anesthesia for digestive endoscopy due to the needs of diagnosis and treatment; 4. ASA classification I-II.

Exclusion criteria

Exclusion criteria: 1. Those who have epistaxis, nasal mucosal injury, nasal space occupying, etc. who cannot perform transnasal carbon dioxide monitoring; 2. There is a clear diagnosis of heart disease (heart failure, angina pectoris, myocardial infarction, arrhythmia, etc.); 3. There are definite lung diseases (asthma, bronchitis, COPD, bullae, pulmonary embolism, lung cancer, etc.); 4. Previous hypotension (systolic blood pressure <= 90mmHg), bradycardia (heart rate <50 beats/min) or hypoxemia (SaO2 <90%); 5. Those with underlying diseases that require oxygen; 6. Multiple trauma; 7. There is a clear upper respiratory tract infection.

Design outcomes

Primary

Measure	Time frame
Incidence of hypoxemia;	—

Countries

China

Contacts

Public ContactWang Hongqian

Shandong Provincial Hospital Affiliated to Shandong First Medical University

wanghongqian1010@163.com+86 15554121951

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026